Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25879050 | 0.89 | OPRM1 (0.45) | ALDH1A1DDB1CRBN | |
| SCHEMBL25557239 | 0.85 | OPRM1 (0.50) | ALDH1A1DDB1CRBN | |
| SCHEMBL25106780 | 0.82 | DDB1 (0.43) | ALDH1A1DDB1CRBNKMT2A | |
| SCHEMBL24758766 | 0.81 | ALDH1A1 (0.47) | ALDH1A1DDB1CRBN | |
| SCHEMBL31297843 | 0.80 | DDB1 (0.51) | ALDH1A1DDB1CRBNMAPK1L3MBTL1 | |
| SCHEMBL25707989 | 0.79 | ALDH1A1 (0.49) | ALDH1A1DDB1CRBNMAPK1L3MBTL1 | |
| SCHEMBL25684698 | 0.78 | ALDH1A1 (0.45) | ALDH1A1DDB1CRBNHTR2C | |
| SCHEMBL25684800 | 0.78 | DDB1 (0.50) | ALDH1A1DDB1CRBNMAPK1L3MBTL1 | |
| SCHEMBL25793979 | 0.77 | OPRM1 (0.54) | ALDH1A1 | |
| SCHEMBL25636414 | 0.77 | NPC1 (0.38) | ALDH1A1DDB1CRBNHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159510-A1 | NOVEL PRMT5 INHIBITORS | AMGEN INC. (US) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159510-A1 | NOVEL PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | ALDH1A1 3191/4885DDB1 856/4885CRBN 831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.